key: cord-0297890-mmx96xim authors: Sandoval, J. L.; Friedlaender, A.; Addeo, A.; Weiss, G. J. title: Payments to key opinion leader physicians and drug sales of top pharmaceutical companies during the COVID-19 pandemic date: 2022-01-10 journal: nan DOI: 10.1101/2022.01.08.22268942 sha: bbb5a9454c46b5e90b9665e6d2a2bf0b3b9d1510 doc_id: 297890 cord_uid: mmx96xim Background: The unprecedented context of the COVID-19 pandemic poses the opportunity to study several questions in circumstances that would probably not otherwise occur. We sought to determine the dynamics of pharmaceutical company drug sales revenue, market capitalization and payments to physicians during the pandemic, focusing on payments to so-called key opinion leaders (KOLs). Methods: We analyzed the CMS Open Payments data of 15 top pharmaceutical company general payments to US physicians. We calculated total payments per year for all physicians, KOLs and 2018 KOLs in subsequent years. Drug-related fold changes in payments, drug revenues and company market capitation were calculated using Q1-2018 as reference. Yearly differences in payments, drug sales revenue and market capitalization were tested using generalized estimation equations (GEE). A double-sided p<0.05 was considered significant. Results: The analyzed dataset comprised 8,563,872 payments to 382,779 physicians. In 2020, we observed a reduction in payments to physicians and KOLs compared to prior years. The total amount per KOL physician per company also decreased for each year for KOLs and the 2018 KOLs in the subsequent years. Payments per drug, but neither drug revenues nor pharmaceutical company market capitalization, followed a downward trend in 2020 compared to prior years. GEE analysis confirmed that, compared to 2018, the decrease in payments to KOLs overall and for the top drugs of each company was statistically significant. Yet, no significant differences in drug sales revenue and market capitalization was observed. Conclusions: A substantial and significant reduction in payments to KOLs during the first fiscal year of the COVID-19 pandemic was not associated with a reduction in drug sales revenue of blockbuster drug products and the market capitalization of 15 top pharmaceutical companies. Overall, these findings suggest that a substantial part of pharmaceutical payments to KOLs do not appear to impact top drug sales revenues. The unprecedented context of the COVID-19 pandemic poses the opportunity to study several questions in circumstances that would probably not otherwise occur. (1, 2) The day-today marketing relationships between physicians and pharmaceutical companies were disrupted, with most medical conferences being cancelled or taking place virtually. (3) Objective We sought to determine the dynamics of pharmaceutical company drug sales revenue, market capitalization and payments to physicians(4) during the pandemic, focusing on payments to so-called key opinion leaders (KOLs). We analyzed the CMS Open Payments data (https://www.cms.gov/openpayments) of 15 top pharmaceutical companies' general payments to US physicians. Since the global reach of the pandemic was evident after March 2020, we considered payments from the second to fourth fiscal quarters of each year. Payments to non-physicians (e.g. dentists, chiropractors) and institutions were excluded. Royalties and ownership bonuses were also excluded. In addition, we excluded Celgene and Boehringer Ingelheim due to the company's acquisition in 2019 (5) and lack of detailed publicly available pharmaceutical sales revenue data, respectively. KOLs were defined as physicians in the top 1% of payments received per pharmaceutical company. We calculated total payments per year for all physicians, KOLs and 2018 KOLs in subsequent years. For KOLs, we determined annual payments per physician per company. We also determined total KOLs' payments related to the top 5 drug products per company based on physician payments. Quarterly revenues records and average market capitalizations were collected from corporate financial reports. Currencies were converted to USD using the quarterly average exchange rate obtained from https://www.stlouisfed.org/. Drug-related fold changes in payments, drug revenues and company market capitation were calculated using Q1-2018 as reference. For drug sales revenue analyses, we excluded drugs lacking data for more than one fiscal quarter. For four drugs, we used Q2-2018 as reference due to Q1-2018 missing data. Individual physician payments related to multiple drugs were divided by the number of drugs identified for that payment. Yearly differences in payments, drug sales revenue and market capitalization were tested using generalized estimation equations (GEE). Data were analyzed with R (v4.1.0) using the geepack package. A double-sided p<0.05 was considered significant. The analyzed dataset comprised 8,563,872 payments to 382,779 physicians. In 2020, we observed a reduction in payments to physicians and KOLs compared to prior years ( Figure 1A) . The total amount per KOL physician per company also decreased for each year's KOLs and the 2018 KOLs in the subsequent years ( Figure 1B) . Total payments related to the top 5 drugs of each company also decreased during 2020 (Figure 1C) . Payments per drug also followed a downward trend in 2020 compared to prior years ( Figure 1D) . However, the drug revenues of the analyzed drugs did not follow this negative trend (Figure 2A-B) . Consequently, pharmaceutical companies' market capitalization did not reflect the downward trend in physician payments ( Figure 2C) . GEE analysis confirmed that, compared to 2018, the decrease in payments to KOLs overall and for the top drugs of each company was statistically significant (Figure 1E ). Yet, no significant differences in drug sales revenue and market capitalization was observed (Figure 2D ). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268942 doi: medRxiv preprint A substantial and significant reduction in payments to KOLs during the first fiscal year of the COVID-19 pandemic was not associated with a reduction in drug sales revenue of blockbuster drug products and the market capitalization of 15 top pharmaceutical companies. Overall, these findings suggest that a substantial part of pharmaceutical payments to KOLs do not appear to impact top drug sales revenues. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268942 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268942 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268942 doi: medRxiv preprint Changes in U.S. air pollution during the COVID-19 pandemic Pandemic and the Incidence of Acute Myocardial Infarction Covid-19: Medical conferences around the world are cancelled after US cases are linked to Massachusetts meeting Let the Sun Shine In! An Adventure in Open Payments Public biotech 2018-the numbers